Salarius Pharmaceuticals, Inc. Banner Image

Salarius Pharmaceuticals, Inc. has reached its limit for free report views

Work for Salarius Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Salarius Pharmaceuticals, Inc.

  • Ticker SLRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Salarius Pharmaceuticals, Inc. Logo Image
  • 1-10 Employees
  • Based in Houston, Texas
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, forMore which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).
4.7 / 5.0 (110)

Salarius Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.7 based on 110 reviews.

Salarius Pharmaceuticals, Inc.

Most Recent Annual Report

Salarius Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Salarius Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Salarius Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!